← Back to Search

Ketamine for Dissociative Symptoms

Phase 1

Recruiting

Led By Karl Deisseroth, MD, PhD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age >18 years old.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 week

Awards & highlights

All Individual Drugs Already Approved

Approved for 5 Other Conditions

No Placebo-Only Group

Summary

This trial will investigate how ketamine causes dissociative symptoms by looking at how it affects the brain.

Who is the study for?

This trial is for adults over 18 with epilepsy who are in the Stanford Epilepsy Monitoring Unit. It's not suitable for those who can't communicate in English, are pregnant or nursing, have had bad reactions to ketamine before, or have a history of psychotic or bipolar disorders.

What is being tested?

The study focuses on understanding how ketamine may cause dissociative symptoms among epilepsy patients. Participants will receive ketamine under controlled conditions while their responses and experiences are closely monitored.

What are the potential side effects?

Ketamine can lead to side effects such as feeling disconnected from reality (dissociation), changes in perception, confusion, agitation, drowsiness, increased blood pressure and heart rate.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 week

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 week

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale)

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Approved for 5 Other Conditions

This treatment demonstrated efficacy for 5 other conditions.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: KetamineExperimental Treatment1 Intervention

Study participants will receive 0.5mg/kg of ketamine - one single infusion

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ketamine

FDA approved

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,474 Previous Clinical Trials

17,501,920 Total Patients Enrolled

16 Trials studying Epilepsy

1,203 Patients Enrolled for Epilepsy

Karl Deisseroth, MD, PhD1.01 ReviewsPrincipal Investigator - Stanford University

Stanford University

1 Previous Clinical Trials

120 Total Patients Enrolled

1Patient Review

I was very uncomfortable around him. He was dismissive of my concerns about side effects and just increased the dosage. He spoke to me in a condescending way and made personal and sexual accusations. I would not recommend him to anyone.